Shots:
- Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021
- The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests
- The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics automation to accelerate growth and deliver more personalized treatment for women
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post Hologic to Acquire Biotheranostics for ~$230M first appeared on PharmaShots.
